Compare
Emmaus Life Sciences, Inc. vs Tonix Pharmaceuticals Holding Corp. vs Jaguar Health, Inc. vs CV Sciences, Inc.
| Latest fiscal year | Emmaus Life Sciences, Inc. EMMA | Tonix Pharmaceuticals Holding Corp. TNXP | Jaguar Health, Inc. JAGX | CV Sciences, Inc. CVSI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.45M | $13.11M | $11.51M | $13.79M |
| Revenue growth (YoY) | -25.2% | +29.8% | -1.5% | -12.2% |
| Gross margin | 93.1% | 49.3% (computed) | 67.2% (computed) | 49.0% |
| Operating margin | 1.9% | -959.1% | -398.8% | -3.4% |
| Net margin | -60.2% | -946.2% | -465.4% | -6.9% |
| Net income | -$7.49M | -$124.02M | -$53.58M | -$958.0K |
| EPS (Diluted) | -$0.12 | -$14.57 | -$22.97 | -$0.01 |
| Operating cash flow | -$11.0K | -$99.84M | -$23.69M | -$407.0K |
| Free cash flow | -$12.0K | -$103.21M | n/a | -$516.0K |
| Cash & equivalents | $2.13M | $207.64M | $968.0K | n/a |
| Total assets | $21.44M | $277.17M | $38.32M | $6.96M |
| Total liabilities | $85.04M | $32.02M | $57.01M | $5.49M |
| Shareholders' equity | -$63.61M | $245.15M | -$18.69M | $1.47M |
| Return on year-end equity | n/a | -50.6% | n/a | -65.3% |
| Shares outstanding | 70.19M | 12.79M | n/a | 184.26M |
Revenue, most recent five fiscal years
| Fiscal year | Emmaus Life Sciences, Inc. | Tonix Pharmaceuticals Holding Corp. | Jaguar Health, Inc. | CV Sciences, Inc. |
|---|---|---|---|---|
| Latest | $12.45M Ended 2025-12-31 | $13.11M Ended 2025-12-31 | $11.51M Ended 2025-12-31 | $13.79M Ended 2025-12-31 |
| 1 year earlier | $16.65M Ended 2024-12-31 | $10.09M Ended 2024-12-31 | $11.69M Ended 2024-12-31 | $15.71M Ended 2024-12-31 |
| 2 years earlier | $29.60M Ended 2023-12-31 | $7.77M Ended 2023-12-31 | $9.76M Ended 2023-12-31 | $16.00M Ended 2023-12-31 |
| 3 years earlier | $18.39M Ended 2022-12-31 | n/a | $11.96M Ended 2022-12-31 | $16.20M Ended 2022-12-31 |
| 4 years earlier | $20.61M Ended 2021-12-31 | n/a | $4.33M Ended 2021-12-31 | $20.05M Ended 2021-12-31 |